MiniMed Group Reports $3.1B FY26 Revenue, But EPS Worsens to $(1.30)
MMED sits 38% above its 52-week low of $10.65.
Summary
MiniMed Group reported fiscal 2026 revenue of $3.102 billion, a 14.2% increase year-over-year. Despite strong top-line growth driven by continuous glucose monitoring (CGM) and consumables, the company's net loss widened significantly to $(333) million, resulting in a diluted loss per share of $(1.30). This follows the 10-K filing earlier today and prior news indicating strong full-year sales but also widening losses. The worsening profitability, partly due to one-time charges, is a key concern despite product momentum like recent FDA clearances.
At the time of this announcement, MMED was trading at $14.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1B. The 52-week trading range was $10.65 to $19.05. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.